Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
31 juil. 2023 07h00 HE
|
Cyclerion Therapeutics, Inc.
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease...
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
01 juin 2023 16h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq...
Cyclerion Announces Reverse Stock Split
15 mai 2023 13h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse...
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
11 mai 2023 18h00 HE
|
Cyclerion Therapeutics, Inc.
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its...
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
03 avr. 2023 07h30 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent...
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
27 mars 2023 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases,...